

# Commonly Prescribed Hepatitis C Treatment Options and Considerations

Treatment Option	# of pills/day	Treatment Length	What Genotypes ?	Special Considerations	Use with Decompensated Cirrhosis?	Use in Severe Renal Disease (GFR < 30)?*
<a href="#">Elbasvir/Grazoprevir (Zepatier™)</a> Click on medication below for prescribing information	1	12-16 weeks	1, 4	Note: Check drug interactions with all <a href="http://Hep-druginteractions.org">Hep-druginteractions.org</a> If genotype 1a, test for NS5A RAS prior to treatment	No	Yes
<a href="#">Glecaprevir/Pibrentasvir (Mavyret™)</a>	3 at same time with food	8-12 weeks	All	Not to use with ethinyl estradiol containing meds such as combined oral contraceptives	No	Yes
<a href="#">Ledipasvir/Sofosbuvir (Harvoni®)</a>	1	8-12 weeks	1, 4, 5, 6	Acid sensitive. See PI for specific info re: dosing PPIs/acid reducing agents	Yes*	Yes
<a href="#">Sofosbuvir/Velpatasvir (Epclusa®)</a>	1	12 weeks	All	Acid loving. PPI use not recommended. See PI for specific info re: PPIs/acid reducing agents RAS testing G3 cirrhosis	Yes*	Yes
<a href="#">Sofosbuvir/Velpatasvir/Voxelaprevir (Vosevi®)</a>	1	12 weeks	All	For use in re-treatment of HCV	No	Yes

Note: All treatment options had sustained virologic response rates of 94% or better in clinical trials. Side effects commonly seen were headache and fatigue (>10% in clinical trials).

\*Taken with ribavirin. Consult Liver Disease Specialist before prescribing in decompensated cirrhosis.